- Record: found
- Abstract: not found
- Article: not found
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
John F. Seymour ,
Thomas J. Kipps ,
Barbara Eichhorst ,
Peter Hillmen ,
James D’Rozario ,
Sarit Assouline ,
Carolyn Owen ,
John Gerecitano ,
Tadeusz Robak ,
Javier De la Serna ,
Ulrich Jaeger ,
Guillaume Cartron ,
Marco Montillo ,
Rod Humerickhouse ,
Elizabeth A. Punnoose ,
Yan Li ,
Michelle Boyer ,
Kathryn Humphrey ,
Mehrdad Mobasher ,
Arnon P. Kater
March 22 2018
March 22 2018
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed
and that is central to the survival of chronic lymphocytic leukemia cells. We evaluated
the efficacy of venetoclax in combination with rituximab in patients with relapsed
or refractory chronic lymphocytic leukemia.